Table 1.

Clinical, chromosomal LOH information of radiation-associated AML patients.

Case	Group	Sex/Age, yearsa	FAB type	Blast cells in bone marrow, %	Latency time, yearsb	OS, days	LOH regions			Gains without LOH
							Loss	Copyneutral aberration	Gain
1	V	M/71	M0	60	14	7	5q14.1-5q22.1 5q23.2-5qter	1p36.11-1p34.3 6q15-6q16.1 8p22-8pter		8p11.21-8q24.3
2	CW	M/67	M0	82	18	28		1p14-1p12
3	CW	M/60	M0*	90	16	15	5q21-5q34 7 12p12.3-12p13.31 19p12-19q13.11			19q13.41-19q13.43
4	CW	M/59	M1	100	16	56		4q26-4q28.1
5	V	F/26	M1	77	17	213+
6	CW	M/66	M2	20	16	36		4q26-4q28.1 7p11-7qter 11q12.1-11q12.3 14q13.2-14q21.3
7	CW	M/76	M2	44	15	3
8	CW	M/73	M2*	20	17	115	5q14.1-5q34 7p21-7q36.1 12q14.3-12q23.3 16q12.1-16q22.1 16q23.1-16q23.1
9	CW	M/55	M2	61	18	49		12qcen-12q12.1		8p11.21-8q24.3
10	V	M/33	M4	70	12	615+		3p26-3p24.3 3q26.31-3q26.33
11	CW	M/59	M4	66	11	304		6p22.2-6p21.31 9p13.1-9q22.32 14q24.3-14q31.2
12	V	M/29	M4*	58	16	55	7	2q12.3-2q14.3
13	CW	M/62	M4	93	16	618		6p25.1-6p24.1
14	CW	M/35	M5a	95	11	247	5q21-5q33.1 17q11.2-17q25.3	11p11.12-11p11.2		8p11.21-8q24.3
15	CW	M/43	M5a	97	17	14+		11p11.12-11p11.2
16	V	M/57	M5a*	32	16	357
17	V	M/42	M5b	100	15	7+		21q11.2-21qter		13q22.1-13q34
18	CW	M/42	M6*	8	17	50	3p12.1-3pter 3q11.2-3q13.31 5q14.3-5qter 7p12.3-7p22 7q31.32-7q36.3 13q13.3-13q14.3		7q23.3-7q31.31 13q14.3-13q21.3
19	CW	M/42	M6*	66	9	78	5q14.2-5q15 5q23.2-5q31.3 5q33.2-5q33.3 13q14.1-13q14.11	2q12.1-2q12.3 7p14.3-7p14.1 15q11.2-15qter 16q13-16q22.1 16q22.2-16q23.2	13q2.33-13q31.3

FAB: French-American-British, V: victim, indicates patient evacuated from the Chernobyl exclusion zone or domicited in highly contaminated with radioactive fallout rural areas of the Ukraine, CW: clean-up worker of the Chernobyl accident, M: male, F: female;

^aat time of diagnosis;

^btime since first exposure due to the Chernobyl accident to overt AML;

^*preceded by myelodysplastic syndrome (MDS);

⁺censored.